Ozgu Arslan/iStock by way of Getty Images
Seres Therapeutics (NASDAQ:MCRB) rose 7% on a report that Nestlé (OTCPK:NSRGY) made an acquisition offer for the corporate that was rebuffed.
Nestlé (OTCPK:NSRGY) provided between $6 and $6.50 a share or an about $750 million for Seres (MCRB), in response to a Betaville “uncommon” alert on Friday, merchants instructed Seeking Alpha.
Even at a $6 a share, an offer would symbolize 567% premium to Seres (MCRB) closing worth on Thursday.
The report comes after Seres (MCRB) introduced final month that Nestlé Health Science, a unit of client care big Nestlé (OTCPK:NSRGY), agreed to buy its oral microbiome remedy Vowst for $175 million.
Seres (MCRB) has brief curiosity of 11%.
More on Seres Therapeutics
Source: Seekingalpha